Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sellas Life Sciences Group Inc (SLS)

Sellas Life Sciences Group Inc (SLS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 71,055
  • Shares Outstanding, K 20,536
  • Annual Sales, $ 7,600 K
  • Annual Income, $ -20,700 K
  • 60-Month Beta 1.74
  • Price/Sales 9.73
  • Price/Cash Flow N/A
  • Price/Book 18.37
Trade SLS with:

Options Overview Details

View History
  • Implied Volatility 130.60% ( +2.36%)
  • Historical Volatility 102.26%
  • IV Percentile 88%
  • IV Rank 68.58%
  • IV High 159.93% on 03/09/22
  • IV Low 66.57% on 04/19/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 108
  • Volume Avg (30-Day) 267
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 15,546
  • Open Int (30-Day) 15,102

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.30
  • Growth Rate Est. (year over year) +333,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.10 +51.19%
on 05/11/22
3.70 -14.19%
on 05/20/22
+0.15 (+5.13%)
since 04/22/22
3-Month
2.10 +51.19%
on 05/11/22
7.40 -57.09%
on 03/22/22
-2.65 (-45.45%)
since 02/23/22
52-Week
2.10 +51.19%
on 05/11/22
15.08 -78.94%
on 06/30/21
-6.57 (-67.44%)
since 05/21/21

Most Recent Stories

More News
SELLAS Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

- Enhanced Pipeline with New Asset, GFH009, an In-licensed Next-Generation, Highly Selective CDK9 Inhibitor - - $25 Million of Gross Proceeds from Capital...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Launches Expanded Access Program for Galinpepimut-S

Physicians To Have Pre-Approval/Expanded Access to Galinpepimut-S (GPS) for Treatment of Patients with Acute Myeloid Leukemia (AML)...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences’ Newly Licensed GFH009 Asset Shows Significant Anti-Leukemic Effect in Acute Myeloid Leukemia Patients Relapsed/Refractory to Venetoclax in Ongoing Phase 1 Study

- Fifth Dose Level Cohort of GFH009, a Highly Selective CDK9 Inhibitor, Initiated - - No Dose-Limiting Toxicities in First Four Dose Levels - NEW...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Announces Achievement of Development Milestone for Approval of IND for Galinpepimut-S in China

SELLAS to Receive $1 Million Milestone Payment in Second Quarter 2022...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Provides Business Update and First Quarter 2022 Highlights

– In-licensed Next-Generation, Highly Selective CDK9 Inhibitor – – Closed Underwritten Public Offering with Gross Proceeds of $25 Million – ...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Announces Pricing of $25.0 Million Underwritten Public Offering

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Announces Proposed Underwritten Public Offering

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Signs Exclusive License Agreement with GenFleet Therapeutics for Next-Generation, Highly Selective CDK9 Inhibitor

- SELLAS In-licenses Worldwide Rights Outside of Greater China for Clinical-Stage Asset - - Completion of Ongoing Phase 1 Trial in the United...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Announces Completion of Enrollment of Phase 1/2 Clinical Trial of GPS in Combination with Pembrolizumab in Advanced Metastatic Ovarian Cancer

Joint Development Committee of SELLAS and Merck Agreed on Study Completion and Overall Operational Path Towards Data Analysis Interim Data for 15...

SLS : 3.17 (-8.24%)
SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China

Chinese Partner, 3D Medicines, Expects to Initiate Trial in Second Half of 2022 in Patients with Hematological Malignancies Who Achieved Objective Response...

SLS : 3.17 (-8.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

SELLAS Life Sciences Group is a development-stage biopharmaceutical company. It focused on novel cancer immunotherapeutics for cancer indications. The company's product candidate, galinpepimut-S, is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 protein, which is present...

See More

Key Turning Points

3rd Resistance Point 3.76
2nd Resistance Point 3.63
1st Resistance Point 3.40
Last Price 3.17
1st Support Level 3.04
2nd Support Level 2.91
3rd Support Level 2.68

See More

52-Week High 15.08
Fibonacci 61.8% 10.12
Fibonacci 50% 8.59
Fibonacci 38.2% 7.06
Last Price 3.17
52-Week Low 2.10

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar